FGF1ΔHBSprevents Diabetic Cardiomyopathy by Maintaining Mitochondrial Homeostasis and Reducing Oxidative Stress Via AMPK/Nur77 Suppression

Dezhong Wang,Yuan Yin,Shuyi Wang,Tianyang Zhao,Fanghua Gong,Yushuo Zhao,Beibei Wang,Yuli Huang,Zizhao Cheng,Guanghui Zhu,Zengshou Wang,Yang Wang,Jun Ren,Guang Liang,Xiaokun Li,Zhifeng Huang
DOI: https://doi.org/10.1038/s41392-021-00542-2
IF: 39.3
2021-01-01
Signal Transduction and Targeted Therapy
Abstract:As a classically known mitogen, fibroblast growth factor 1 (FGF1) has been found to exert other pleiotropic functions such as metabolic regulation and myocardial protection. Here, we show that serum levels of FGF1 were decreased and positively correlated with fraction shortening in diabetic cardiomyopathy (DCM) patients, indicating that FGF1 is a potential therapeutic target for DCM. We found that treatment with a FGF1 variant (FGF1 ∆HBS ) with reduced proliferative potency prevented diabetes-induced cardiac injury and remodeling and restored cardiac function. RNA-Seq results obtained from the cardiac tissues of db/db mice showed significant increase in the expression levels of anti-oxidative genes and decrease of Nur77 by FGF1 ∆HBS treatment. Both in vivo and in vitro studies indicate that FGF1 ∆HBS exerted these beneficial effects by markedly reducing mitochondrial fragmentation, reactive oxygen species (ROS) generation and cytochrome c leakage and enhancing mitochondrial respiration rate and β-oxidation in a 5’ AMP-activated protein kinase (AMPK)/Nur77-dependent manner, all of which were not observed in the AMPK null mice. The favorable metabolic activity and reduced proliferative properties of FGF1 ∆HBS testify to its promising potential for use in the treatment of DCM and other metabolic disorders.
What problem does this paper attempt to address?